onc brain

The longer read

The question here is the one PROSPECT asked in a lower-risk population, moved into the immunotherapy era: if systemic therapy is active enough, can pelvic RT be left out of neoadjuvant treatment for rectal cancer. It also follows directly from TORCH, which varied where SCRT sat relative to CAPOX and toripalimab but never removed it. The premise in the abstract is functional, that RT plus surgery costs more than either alone, so the bar the no-RT arm has to clear is not equivalence on response but a functional gain large enough to justify whatever response it gives up.

On response, it gives up a lot. Overall CR was 61.5% with SCRT and 37.1% without. The decomposition is more informative than the headline. Among resected pts, pCR was 44.2% vs 32.8%, a real but moderate gap. The larger separation is in clinical responders who went to W&W, 25 vs 7. That matters in two directions. It means the resected-only pCR comparison is biased against the SCRT arm, because its best responders were removed from the surgical denominator before pathology could count them. It also means the trial's advantage for RT rests disproportionately on cCR, the component that is assessor-dependent, unblinded by necessity, and subject to later regrowth.

Several design features should temper confidence in the size of the gap. The analysis is restricted to 148 pts who completed treatment out of 192 enrolled, so it is neither intention-to-treat nor final, and the abstract offers no p-value or interval. The assessment timepoint is not given; an arm that begins with a week of RT before six cycles of systemic therapy may be assessed later from the start of treatment, and elapsed time alone raises response rates in rectal cancer. Four non-cCR pts in the no-RT arm have no resolved outcome. None of these plausibly erases the difference, but each could move it.

The finding the authors foreground, an encouraging CR rate with CAPOX plus a PD-1 inhibitor alone in pMMR disease, is the least secure claim in the abstract. Without a chemotherapy-alone arm there is no way to assign that response to toripalimab rather than to six cycles of CAPOX, and pMMR tumors are the setting where checkpoint inhibition has been least rewarding without a priming stimulus. If anything, the arm comparison reads as indirect support for RT as that stimulus, though the trial cannot separate immune priming from the direct cytoreductive effect of 25Gy/5Fx.

For the functional argument, the early disposition data cut against RT omission. In a cohort where 96.6% had at least one high-risk feature, 58 of 70 pts without RT went to surgery vs 52 of 78 with it, and the no-RT arm retained adjuvant chemoradiotherapy for positive circumferential margins at an unreported rate. Avoiding radiation proctopathy in exchange for more resections is not obviously a functional win, and anorectal function has not been reported. What would overturn the current read is a high regrowth rate among the 25 W&W pts in the SCRT arm, or a functional readout favoring the no-RT arm despite more surgery. RAPIDO is the standing reminder that early response advantages with SCRT-based TNT do not guarantee locoregional control on longer follow-up, and that is the readout to wait for.